Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2

Y. Joseph Woo, Corinna M. Panlilio, Richard K. Cheng, George P. Liao, Erik E. Suarez, Pavan Atluri, Hina W. Chaudhry

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Objective: Heart failure therapies ranging from revascularization to remodeling to replacement are variably effective. Theoretically, endogenous repair via myocardial regeneration would be an ideal therapy. This study examined the ability to initiate regeneration by adenoviral-mediated expression of the cell cycle regulator cyclin A2. Our prior studies have demonstrated robust cyclin A2 transgene expression and marked antiphosphorylated histone H3 activity with this strategy, indicating the induction of cardiomyocyte mitosis. Methods: Adult male, Lewis rats underwent left anterior descending coronary artery ligation followed by intramyocardial delivery of either cyclin A2 adenoviral vector (n = 8) or empty adeno-null vector as a control (n = 8) into the peri-infarct border zone. In vivo myocardial function was analyzed by echocardiography and invasive left ventricular pressure catheter at 6 weeks, when the animals are traditionally in heart failure. Hearts were explanted for immunoblotting and left ventricular geometric analysis. Cellular proliferation was assessed by proliferating cellular nuclear antigen expression. Results: Cyclin A2 hearts exhibited improved left ventricular function as compared with controls including enhanced cardiac output (32 ± 3.3 vs 26 ± 5.0 mL/min, P < .05), stroke volume (0.16 ± 0.04 vs 0.11 ± 0.04 mL, P < .05), ejection fraction (72% ± 7.4% vs 46.% ± 8.5%, P < .05), fractional shortening (35% ± 5.4% vs 19% ± 4.3%, P < .002), maximum pressure (72 ± 9.3 vs 61 ± 2.9 mm Hg, P < .05), and end-systolic pressure (67 ± 7.0 vs 55 ± 7.0 mm Hg, P < .05). Enhanced myocardial preservation was demonstrated by enhanced left ventricular border zone wall thickness. Increased myocardial proliferation was evidenced by increased expression of proliferating cell nuclear antigen expression in cyclin A2-treated hearts. Conclusions: In failing hearts, targeted delivery of cyclin A2 improves hemodynamic function, as measured by echocardiography and pressure catheter analysis, preserves ventricular wall thickness, and may serve as an ideal myocardial regenerative therapy.

Original languageEnglish (US)
Pages (from-to)927-933
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume133
Issue number4
DOIs
StatePublished - Apr 2007

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2'. Together they form a unique fingerprint.

Cite this